Epidoxorubicin and Cyclosporin-A in Colorectal Cancer
Author Information
Author(s): J. Verweijl, H. Herweijerl, R. Oosterom, M.E.L. van der Burg, A.S.Th. Planting, C. Seynaeve, G. Stoter, K. Nooterl
Primary Institution: Rotterdam Cancer Institute/Daniel den Hoed Kliniek
Hypothesis
Can cyclosporin-A reverse multidrug resistance in colorectal cancer patients receiving epidoxorubicin?
Conclusion
The combination of cyclosporin-A and epidoxorubicin did not show significant effectiveness in treating colorectal cancer.
Supporting Evidence
- Only one partial response was observed in the study.
- Median cyclosporin-A peak blood levels were 6248 ng/ml.
- 33% of patients experienced severe leucocytopenia.
Takeaway
Doctors tried to use a drug called cyclosporin-A to help another drug work better for cancer, but it didn't really help the patients.
Methodology
Patients received cyclosporin-A followed by epidoxorubicin, with drug levels monitored and responses evaluated after two cycles.
Limitations
The study had a small sample size and only one partial response was observed.
Participant Demographics
Median age was 56 years, with 13 males and 11 females.
Want to read the original?
Access the complete publication on the publisher's website